Previous 10 | Next 10 |
MEDFORD, N.Y., May 07, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the approval of its DPP Dengue System by Agência Nacional de Vigilância Sanitária (ANVISA), Br...
Chembio Diagnostics, Inc. (CEMI) Q1 2019 Earnings Conference Call May 01, 2019, 16:30 ET Company Participants Philip Taylor - IR John Sperzel - President, CEO & Director Neil Goldman - EVP & CFO Conference Call Participants Kyle Bauser - Dougherty & Company Pe...
Chembio Diagnostics (NASDAQ: CEMI ): Q1 GAAP EPS of -$0.16 misses by $0.01 . More news on: Chembio Diagnostics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
MEDFORD, N.Y., May 01, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended March 31, 2019. Recent Accomplishments & Highlights Achiev...
MEDFORD, N.Y., April 22, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the first quarter of 2019 after the close of trading on Wednesda...
Agência Nacional de Vigilância Sanitária ((ANVISA)), Brazil’s health regulatory agency approves Chembio Diagnostics' (NASDAQ: CEMI ) DPP Zika/Dengue/Chikungunya System. More news on: Chembio Diagnostics, Inc., Healthcare stocks news, Stocks on the move, Read mor...
MEDFORD, N.Y., April 09, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the approval of its DPP Zika/Dengue/Chikungunya System by Agência Nacional de Vigilância Sanit...
MEDFORD, N.Y., April 02, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that the company has entered into an agreement with Perseus Science Group LLC, to advance the development o...
Call Start: 16:30 Call End: 17:03 Chembio Diagnostics, Inc. (CEMI) Q4 2018 Earnings Conference Call March 7, 2019 04:30 PM ET Company Participants Philip Taylor - IR John Sperzel - President, CEO Neil Goldman - CFO Conference Call Participants Per Ostlund - Craig-Hallum...
Chembio Diagnostics (NASDAQ: CEMI ): Q4 GAAP EPS of -$0.21 misses by $0.04 . More news on: Chembio Diagnostics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Chembio Diagnostics Inc. Company Name:
CEMI Stock Symbol:
NASDAQ Market:
Chembio Diagnostics Inc. Website:
Chembio Diagnostics, Inc. becomes the first North American structure controlled by Biosynex in North America STRASBOURG, France, April 27, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and distribution of ...
MEDFORD, N.Y., April 19, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders concerning the pending tender offer by Biosynex SA. April 19, 2023 ...
MEDFORD, N.Y., April 10, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders concerning the pending tender offer by Biosynex SA. April 10, 2023 ...